NCT02824354 (NalmeCir) is a Phase 3 clinical trial of Nalmefene (Selincro®) 18 mg tablet in Cirrhosis, sponsored by Centre Hospitalier Universitaire, Amiens.

Who is sponsoring NCT02824354?

NCT02824354 is sponsored by Centre Hospitalier Universitaire, Amiens.

What drugs are being tested in NCT02824354?

Interventions in NCT02824354: Nalmefene (Selincro®) 18 mg tablet, placebo.

What condition does NCT02824354 study?

NCT02824354 studies Cirrhosis, Alcohol Dependence, Nalmefene.

Is NCT02824354 still recruiting?

NCT02824354 is currently withdrawn. Last updated 20 July 2023.

Last reviewed 2023-07-20 · How we verify

NCT02824354: NalmeCir

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

Withdrawn Phase 3 Last updated 20 July 2023

What this trial tests

Phase 3 trial testing Nalmefene (Selincro®) 18 mg tablet in Cirrhosis. Withdrawn.

Timeline

1 December 2018

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 December 2018
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across France

Drugs / interventions tested

Nalmefene (Selincro®) 18 mg tablet — full drug profile →
placebo

Conditions studied

Cirrhosis — all drugs for Cirrhosis →
Alcohol Dependence — all drugs for Alcohol Dependence →
Nalmefene — all drugs for Nalmefene →

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, any sex, with Cirrhosis or Alcohol Dependence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.
Xiao J, Wang F, Wong NK, Lv Y, et al · · 2020 · cited 28× · PMID 32690129 · DOI 10.3727/105221620x15952664091823
From gene networks to drugs: systems pharmacology approaches for AUD.
Ferguson LB, Harris RA, Mayfield RD. · · 2018 · cited 11× · PMID 29497781 · DOI 10.1007/s00213-018-4855-2

Verify or expand the search:

Other recruiting trials for Cirrhosis

Currently open trials in the same condition.

NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
NCT07071662 — Induction of Labor in Breech Presentation · completed
NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02824354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
Last refreshed: 20 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02824354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing